Abstracts tagged "autoimmune diseases"

Abstract Number: 2512 • ACR Convergence 2023
Targeted Therapies for Severe Immune-related Adverse Events of Immune Checkpoint Inhibitors Are Not Associated with a Worse Prognosis
Jacques-Eric Gottenberg¹, Nathanaël Sedmak², Pierre Tran Ba Loc², Thibaut Fabacher², Thibaut Bahougne², Cécile Arnold², Guillaume Desjeux³, Hervé Servy⁴, Nicolas Meyer², Erik Sauleau², Raphaele Seror⁵ and Eden Sebbag⁶, ¹Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ²Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³e-Health Services Sanoia, Gemenos, France, ⁴e-Health Services Sanoia, La Ciotat, France, ⁵University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ⁶Université de Strasbourg, Strasbourg, France
Background/Purpose: In about 10% of patients, the immune response to immune checkpoint inhibitors (ICI) exceeds the anti-tumor response and leads to autoimmune complications (immune-related Adverse…
Abstract Number: 0039.5 • ACR Convergence 2023
Cytokine-induced Transcriptome Modification Elucidates the Similarity and Dissimilarity Across 10 Immune-related Diseases
Haruka Takahashi¹, Hiroaki Hatano², Masahiro Nakano³, Haruka Tsuchiya⁴, Mineto Ota⁴, Tomohisa Okamura⁵, Keishi Fujio⁴ and Kazuyoshi Ishigaki⁶, ¹Laboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences and Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Laboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan, ³Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan, ⁴Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁵Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁶RIKEN, Tokyo, Japan

Background/Purpose: Abnormal cytokine regulation is the fundamental pathology of immune-mediated diseases (IMDs). Clinical transcriptome data has a potential to monitor real-time cytokine pathway activities of…
Abstract Number: 0119 • ACR Convergence 2023
Mortality-related Health Metrics in Systemic Autoimmune Diseases: An Epidemiological Analysis of a Nationwide Register-based Cohort
Mucong Li¹, Chanyuan Wu², Peng Yin³, Qian Wang⁴, Dong Xu⁵, Xiaomei Leng², Xinping Tian¹, Ali Duarte-Garcia⁶, Mengtao Li¹, xiaofeng Zeng⁴ and Maigeng Zhou³, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Peking Union Medical College Hospital, Beijing, China, ³Chinese Center for Disease Control and Prevention, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁵Department of Rheumatology, Peking Union Medical College, Beijing, China, ⁶Mayo Clinic, Rochester, MN
Background/Purpose: Systemic autoimmune diseases (sAIDs) have become leading contributors to premature death. Meanwhile, regional disparities exist in capacity of rheumatology healthcare services delivery. However, no…
Abstract Number: 0228 • ACR Convergence 2023
A Comprehensive Retrospective Analysis of Polymyalgia Rheumatica in Long COVID Patients at an Academic Medical Center in the Midwest
Hanan Ibrahim¹ and Alireza Meysami², ¹Henry Ford Health System (HFHS), Detroit, MI, ²Henry Ford Health, Detroit, MI
Background/Purpose: Polymyalgia Rheumatica (PMR) is an inflammatory disorder that predominantly affects older adults. Incidence peaks at 70-80 years old [1] and is more common in…
Abstract Number: 0467 • ACR Convergence 2023
Cardiovascular Events During Pregnancy: Implications for Adverse Pregnancy Outcomes in Individuals with Autoimmune Rheumatic Diseases and Antiphospholipid Syndrome
Rashmi Dhital, Rebecca Baer and Christina Chambers, University of California San Diego, La Jolla, CA
Background/Purpose: Autoimmune rheumatic diseases (ARD) and antiphospholipid syndrome (APS) are autoimmune conditions with increased risks of cardiovascular complications as well as negative pregnancy consequences. We…
Abstract Number: 0607 • ACR Convergence 2023
CAR T Cell Therapy Leads to Long-term Abrogation of Autoimmunity in SLE Patients While Vaccination Responses Are Maintained
Georg Schett¹, Luis Munoz², Jule Taubmann³, Michael Aigner⁴, Christina Bergmann⁵, Johannes Knitza⁶, Gerhard Kroenke⁷, Dagmar Werner², Fabian Müller⁸ and Andreas Mackensen⁴, ¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ²FAU Erlangen-Nürnberg, Erlangen, Germany, ³Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁴Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁵Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁶Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁷Charite Berlin, Berlin, Germany, ⁸Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: We have previously shown that CD19 CAR T cell therapy leads to stable drug-free remission of treatment-resistant SLE (1,2). Based on these findings we…
Abstract Number: 0904 • ACR Convergence 2023
KYV-101, a Fully Human Anti-CD19 CAR T Cell Therapy, Demonstrates CAR-Mediated and CD19-Dependent Activity Against Autologous B Cells from Patients with Autoimmune Disease
Soo Park¹, Gloria Lutzny-Geier², Natalia Giltiay¹, Jazmin Bravo¹, Simone Sandoval¹, Joseph Cheng¹, Catherine Dong¹, Nicole Khoshnoodi¹, Ames Register¹, Daniel Anaya¹, Michael Aigner³, Andreas Mackensen³, Georg Schett⁴, Charles Kaplan¹, Dominic Borie¹, James Chung¹ and Tom Van Blarcom⁵, ¹Kyverna Therapeutics, Emeryville, CA, ²Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁴Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁵Kyverna Therapuetics, Emeryville, CA
Background/Purpose: A significant unmet need remains in the treatment of relapsed and/or refractory B cell-driven autoimmune diseases, including systemic lupus erythematosus (SLE),systemic sclerosis (SSc), and…
Abstract Number: 1060 • ACR Convergence 2023
Impact of Troponin Monitoring on Cardiac Outcomes in Patients Receiving Immune Checkpoint Inhibitors
Maja Ivanovic¹, Antonia Chan², Miguel Franquiz¹, Sidra Xu³, Carissa Lee³, Muhammad Fazal⁴, Jonathan You¹, Ronald Witteles⁴, Joel Neal⁵, Sean Wu⁴, Sarah Waliany¹ and Han Zhu⁴, ¹Department of Medicine, Stanford University, Stanford, CA, ²Stanford Medical School, Stanford, CA, ³Stanford University, Stanford, CA, ⁴Department of Cardiology, Stanford University, Stanford, CA, ⁵Department of Oncology, Stanford University, Stanford, CA
Background/Purpose: Immune checkpoint inhibitors (ICI) are an increasingly used form of anti-cancer therapy, but they have been associated with a range of cardiac immune-related adverse…
Abstract Number: 1215 • ACR Convergence 2023
Efficacy of Pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases
Bayram Farisogullari¹, Eduardo Santos², Emma Dures³, Rinie Geenen⁴ and Pedro Machado⁵, ¹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra (ESEnfC), Coimbra, Portugal, ³Academic Rheumatology, Bristol Royal Infirmary; and Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ⁴Utrecht University, Vorstenbosch, Netherlands, ⁵Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom
Background/Purpose: To identify the best evidence on the efficacy of pharmacological interventions in reducing fatigue in people with I-RMDs and to summarise their safety in…
Abstract Number: 1491 • ACR Convergence 2023
Targeting the Mevalonate Pathway-dependent Protein Geranylgeranylation to Restrict Follicular Helper T Cell Differentiation for the Treatment of Systemic Lupus Erythematosus
Lai Wang, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China
Background/Purpose: Recent research focusing on follicular helper T (Tfh) cells emphasizes its importance in autoimmune diseases, such as systemic lupus erythematosus (SLE). However, the mechanisms…
Abstract Number: 1672 • ACR Convergence 2023
Association of COVID-19 Vaccinations with Flares of Systemic Rheumatic Disease: A Case-Crossover Study
Genna Braverman¹, Medha Barbhaiya², Minerva Nong¹, Vivian Bykerk³, Nathaniel Hupert⁴, Colby Lewis V⁴ and Lisa Mandl², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Department of Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: Fear of flare contributes to COVID-19 vaccine hesitancy in patients with systemic rheumatic diseases (SRD). Accurately ascertaining post-vaccine SRD flares and differentiating them from…
Abstract Number: 1861 • ACR Convergence 2023
Efficacy of Non-pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases
Eduardo Santos¹, Bayram Farisogullari², Emma Dures³, Rinie Geenen⁴ and Pedro Machado⁵, ¹Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra (ESEnfC), Coimbra, Portugal, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Academic Rheumatology, Bristol Royal Infirmary; and Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ⁴Utrecht University, Vorstenbosch, Netherlands, ⁵Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom
Background/Purpose: To identify the best evidence on the efficacy of non-pharmacological interventions in reducing fatigue in people with I-RMDs and to summarise their safety in…
Abstract Number: 1960 • ACR Convergence 2023
From Clinical Amyopathy to Severe Oropharyngeal Dysphagia in Pure Dermatomyositis: A Greater Extent of Muscle Weakness Is Associated with a Higher Cancer Prevalence
Hao Cheng Shen¹, Victoria Ivensky², Yves Troyanov³, Josiane Bourre-Tessier¹, Farah Zarka², Sabrina Hoa⁴, Jessica Nehme², Jean-Paul Makhzoum⁵, Anne-Marie Mansour², Rosalie-Selene Meunier², Alexandra Mereniuk², Darosa Lim⁶, Jean-Pierre Raynauld¹, Eric Rich¹, Jean-Richard Goulet¹, Marianne Landry⁷, Maude Bouchard-Marmen⁸, Valerie Leclair⁹, Hugues Allard-Chamard¹⁰, Marie Hudson¹¹, Erin O'Ferrall¹², Rami Massie¹², Jason Karamchandani¹³, Benjamin Ellezam¹⁴, Ira N. Targoff¹⁵, Minoru Satoh¹⁶, Marvin Fritzler¹⁷, Jean-Luc Senecal¹, Alain Meyer¹⁸ and Oceane Landon-Cardinal¹, ¹Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ²Hôpital du Sacré-Coeur de Montréal, Université de Montréal, Montreal, QC, Canada, ³Hôpital du Sacré-Coeur de Montréal, Centre hospitalier de l'Université de Montreal (CHUM), Université de Montréal, Montreal, QC, Canada, ⁴University of Montreal, Brossard, QC, Canada, ⁵Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Hôpital de LaSalle, Montreal, QC, Canada, ⁸CHU de Québec, Université Laval, Quebec City, QC, Canada, ⁹Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹⁰Université de Sherbrooke, Sherbrooke, QC, Canada, ¹¹McGill University, Montréal, QC, Canada, ¹²Montreal Neurological Institute, McGill University, Montreal, QC, Canada, ¹³McGill University Health Center (MUHC), McGill University, Montreal, QC, Canada, ¹⁴CHU Sainte-Justine, Université de Montréal, Montreal, QC, Canada, ¹⁵Veteran's Affairs Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁷University of Calgary, Calgary, AB, Canada, ¹⁸Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Background/Purpose: The risk of cancer is increased in patients with pure dermatomyositis (DM), i.e. patients with a DM rash and without an anti-MDA-5 syndrome, a…
Abstract Number: 2278 • ACR Convergence 2023
Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry
Cristiana Sieiro Santos¹, Paula Pérez García², Jose Ordas Martínez², Clara Moriano², Carolina Álvarez Castro² and Elvira Díez Álvarez², ¹Complejo Asistencial Universitario de León, León, Spain, ²CAULE, León, Spain
Background/Purpose: Pregnancy in patients with connective tissue diseases are known to be at high risk for the occurrence of adverse pregnancy outcomes. We aim toevaluate…
Abstract Number: 2513 • ACR Convergence 2023
Latent Class Analysis Identifies 2 Clinical Phenotypes of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Laura Cappelli¹, Jamie Perin², Clifton Bingham³ and Ami Shah⁴, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD
Background/Purpose: : Immune checkpoint inhibitors (ICI) for cancer treatment can cause inflammatory arthritis (IA). ICI-IA is a heterogeneous entity affecting peripheral joints, tendons, and rarely…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].